Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IBT on rights offering
Mandate

Vinge advises IBT on rights offering

April 28, 2016

Infant Bacterial Therapeutics AB (publ) (IBT) carries out a rights offering of SEK 100 million. Vinge advises IBT.

The Vinge team primarily consists of Erik Sjöman and Dain Hård Nevonen (partners, capital markets & public M&A) and associates Ludvig Frithiof, Joel Wahlberg and Astrid Karlsson, and Tora Hansjons (tax).

Related

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

 Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025